SCHEMBL569941

SCHEMBL569941

CCn1nc(-c2ccc(O)cn2)c2ncccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.39
ADORA2A P29274 2/20 0.34
ADORA1 P30542 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
HTR2B P41595 2/20 0.34
ADORA3 P0DMS8 1/20 0.33
RORC P51449 5/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 2/20 0.33
BRD4 O60885 1/20 0.33
MITF O75030 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
IDO1 P14902 1/20 0.33
COMT P21964 1/20 0.33
ALOX12 P18054 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570067 0.82 ESR1 (0.42) ESR1ADORA2APDE1APDE1BPDE1C
SCHEMBL570130 0.80 P4HTM (0.39) KDM4ENPC1L3MBTL1RAB9ANPSR1
SCHEMBL569294 0.79 PDE1A (0.39) ESR1ADORA2AADORA1PDE1APDE1B
SCHEMBL570261 0.77 MEN1 (0.44) ADORA1PDE1APDE1BPDE1CHTR2A
SCHEMBL571142 0.76 TBXAS1 (0.37) ESR1ADORA2APDE1APDE1BPDE1C
SCHEMBL570552 0.72 PDE1A (0.35) PDE1APDE1BPDE1CHTR2AHTR2C
SCHEMBL15065058 0.71 MEN1 (0.40) ADORA2AADORA1PDE1APDE1BPDE1C
SCHEMBL23529924 0.70 PDE1A (0.50) ADORA2APDE1APDE1BPDE1CHTR2A
SCHEMBL29549938 0.70 PDE1A (0.50) ADORA2APDE1APDE1BPDE1CHTR2A
SCHEMBL569526 0.69 GRM2 (0.46) ADORA2APDE1APDE1BPDE1CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601192-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2017-03-01 EP disclosed
US-9029536-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-12 US disclosed
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-04 US disclosed
EP-2601192-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2013-06-12 EP disclosed
WO-2012018909-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172292-A1 FUSED HETEROCYCLIC COMPOUNDS PDE10A, PDE3A, PDE2A ESR1 1158/4885ADORA2A 161/4885ADORA1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.